+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
INFLUX

Influx Healthtech Share Price

 

 

Influx Healthtech live price: ₹241. It opened at ₹229 vs previous close ₹228; intraday high/low: ₹245/₹227. The 50 & 200 DMA stand at ₹245.84/₹213.93.

Influx Healthtech Performance

  • Today's Low
  • ₹227
  • Today's High
  • ₹245
  • 52 Week Low
  • ₹120
  • 52 Week High
  • ₹299
  • Open Price₹229
  • Previous Close₹228
  • Volume46,800
  • 50 DMA₹245.84
  • 100 DMA₹235.20
  • 200 DMA₹213.93

Influx Healthtech Chart

Investment Returns

  • Over 1 Month -17.3%
  • Over 3 Month + 5.55%
  • Over 6 Month -0.07%
  • Over 1 Year + 139.58%

Smart Investing Starts Here Start SIP with Influx Healthtech for Steady Growth!

Invest Now

Influx Healthtech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 27.2
  • PEG Ratio
  • -
  • Market Cap Cr
  • 558
  • P/B Ratio
  • 5.5
  • Average True Range
  • 14.18
  • EPS
  • 8.87
  • Dividend Yield
  • 0
  • MACD Signal
  • -3.69
  • RSI
  • 40.52
  • MFI
  • 30.61

Latest Stock News Updates

Influx Healthtech lists at 38% premium on NSE SME, beats GMP estimates

After the listing, shares of Influx Healthtech were trading at 127.5, down 3.77 per cent from the opening price

Influx Healthtech Financials

Influx Healthtech Technicals

EMA & SMA

Current Price
₹241.00
+ 12.55 (5.49%)
pointer
  • Bearish Moving Average 13
  • Bullish Moving Average 3
  • 20 Day
  • ₹246.10
  • 50 Day
  • ₹245.80
  • 100 Day
  • ₹235.20
  • 200 Day
  • ₹213.90

Resistance and Support

230.5 Pivot Speed
  • R3 245.90
  • R2 241.45
  • R1 234.95
  • S1 224.00
  • S2 219.55
  • S3 213.05

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Influx manufactures nutraceuticals, cosmetics, herbal, veterinary, and homecare products across certified plants., offering contract manufacturing of tablets, capsules, gummies, powders, protein bars, and creams at competitive rates.

Influx Healthtech Ltd has an operating revenue of Rs. 146.83 Cr. on a trailing 12-month basis. An annual revenue growth of 41% is outstanding, Pre-tax margin of 19% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 8% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -12% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 95 which is a GREAT score indicating consistency in earnings, a RS Rating of 83 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 27 indicates it belongs to a strong industry group of Medical-Supplies and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Influx Healthtech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-20 Audited Results
2025-11-12 Quarterly Results

Influx Healthtech Shareholding Pattern

73.53%
0.07%
0.16%
0%
16.13%
10.11%

Influx Healthtech FAQs

Influx Healthtech share price is ₹241 As on 11 June, 2026 | 13:26

The Market Cap of Influx Healthtech is ₹557.9 Cr As on 11 June, 2026 | 13:26

The P/E ratio of Influx Healthtech is 27.2 As on 11 June, 2026 | 13:26

The PB ratio of Influx Healthtech is 5.5 As on 11 June, 2026 | 13:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23